Next-Generation CyTOF XT Redefines Cytometry with Advances in Automation, Throughput, Time to Results and Total Cost of Ownership
25 mai 2021 14h00 HE
|
Fluidigm Corporation
SOUTH SAN FRANCISCO, Calif., May 25, 2021 (GLOBE NEWSWIRE) -- Fluidigm Corporation (NASDAQ:FLDM), an innovative biotechnology tools provider with a vision to improve life through comprehensive...
Imaging Mass Cytometry Utilized by Global Consortium Focused on New Precision Medicine Approaches for Treatment of Rheumatoid Arthritis
24 mai 2021 08h30 HE
|
Fluidigm Corporation
SOUTH SAN FRANCISCO, Calif., May 24, 2021 (GLOBE NEWSWIRE) -- Fluidigm Corporation (NASDAQ:FLDM), an innovative biotechnology tools provider with a vision to improve life through comprehensive...
Fluidigm to Present at Upcoming Investor Conferences
14 mai 2021 08h30 HE
|
Fluidigm Corporation
SOUTH SAN FRANCISCO, Calif., May 14, 2021 (GLOBE NEWSWIRE) -- Fluidigm Corporation (Nasdaq:FLDM), an innovative biotechnology tools provider with a vision to improve life through comprehensive...
Fluidigm Announces Virtual Mass Cytometry Webinar Investor Event on May 24, 2021, at 1:00 p.m. Eastern Time
10 mai 2021 13h30 HE
|
Fluidigm Corporation
SOUTH SAN FRANCISCO, Calif., May 10, 2021 (GLOBE NEWSWIRE) -- Fluidigm Corporation (Nasdaq:FLDM), an innovative biotechnology tools provider with a vision to improve life through comprehensive...
Fluidigm Announces First Quarter 2021 Financial Results with Total Revenue of $32.8 Million, Up 19 Percent Over Prior Year Period
06 mai 2021 16h05 HE
|
Fluidigm Corporation
Forecasting underlying base business growth of 16–17% supported by new product innovation SOUTH SAN FRANCISCO, Calif., May 06, 2021 (GLOBE NEWSWIRE) -- Fluidigm Corporation (Nasdaq:FLDM), an...
Data Published in Nature Communications Demonstrate the Power of Fluidigm’s CyTOF and Imaging Mass Cytometry Technologies to Transform Cancer Drug Discovery and Enable New Precision Medicine Approaches in Clinical Oncology
06 mai 2021 08h30 HE
|
Fluidigm Corporation
SOUTH SAN FRANCISCO, Calif., May 06, 2021 (GLOBE NEWSWIRE) -- Fluidigm Corporation (NASDAQ:FLDM), an innovative biotechnology tools provider with a vision to improve life through comprehensive...
Fluidigm Announces Conference Call and Webcast of First Quarter 2021 Financial Results
08 avr. 2021 08h30 HE
|
Fluidigm Corporation
SOUTH SAN FRANCISCO, Calif., April 08, 2021 (GLOBE NEWSWIRE) -- Fluidigm Corporation (Nasdaq:FLDM), an innovative biotechnology tools provider with a vision to improve life through comprehensive...
FDA Grants Emergency Use Authorization for Home Collection Kit for Advanta Dx SARS-CoV-2 RT-PCR Assay
01 mars 2021 08h30 HE
|
Fluidigm Corporation
Collaboration Agreement to Market AZOVA COVID-19 Test Collection Kit Online AZOVA Digital Health Platform Provides Patient Questionnaire, Process for Prescription, Kit Purchase, Sample Collection,...
Fluidigm Announces Fourth Quarter and Full Year 2020 Financial Results
10 févr. 2021 16h05 HE
|
Fluidigm Corporation
Fourth Quarter Total Revenue Increased 38 Percent to $44.6 million Fourth Quarter Product and Service Revenue Increased 26 Percent to $40.5 million Full Year Total Revenue Increased 18 Percent to...
Fluidigm Announces Collaboration with Zhejiang PuLuoTing Health Technology Co. Ltd to Market Fluidigm CyTOF Technology to Clinical Labs in China
10 févr. 2021 16h02 HE
|
Fluidigm Corporation
SOUTH SAN FRANCISCO, Calif., Feb. 10, 2021 (GLOBE NEWSWIRE) -- Fluidigm Corporation (NASDAQ:FLDM), an innovative biotechnology tools provider with a vision to improve life through comprehensive...